What is Viking Therapeutics?
Founded in 2012, Viking Therapeutics operates as a clinical-stage biopharmaceutical entity dedicated to the development of orally available therapies. The company maintains a robust research and development framework, specifically targeting lipid disorders, X-linked adrenoleukodystrophy, and recovery solutions for orthopedic trauma. By holding exclusive worldwide rights to a diverse array of small-molecule programs, Viking Therapeutics distinguishes itself through a specialized focus on metabolic regulation. Its operational model, which integrates licensed intellectual property with internal clinical expertise, positions the firm as a critical player in the North American biotech sector, consistently advancing its portfolio toward commercial viability.
How much funding has Viking Therapeutics raised?
Viking Therapeutics has raised a total of $24M across 1 funding round:
Stock Offering
$24M
Stock Issuance/Offering (2015): $24M, investors not publicly disclosed
Key Investors in Viking Therapeutics
Undisclosed Investors
What's next for Viking Therapeutics?
With the recent influx of capital, Viking Therapeutics is well-positioned to accelerate its clinical trial milestones and expand its research capabilities. The strategic deployment of these funds will likely prioritize the advancement of its lead metabolic candidates through late-stage testing phases. As the company navigates the complexities of regulatory approval and market entry, the focus will remain on scaling its operational infrastructure to support the transition from a research-heavy organization to a more mature, product-oriented biopharmaceutical enterprise. Investors will be monitoring the progression of its pipeline, particularly regarding the efficacy data for its primary metabolic programs, which remain central to the company's long-term value proposition.
See full Viking Therapeutics company page
